Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prion protein amyloidosis

B Ghetti1, P Piccardo, B Frangione

  • 1Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis 46202-5120, USA.

Brain Pathology (Zurich, Switzerland)
|April 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conformation as therapeutic target in the prionoses and other neurodegenerative conditions.

Methods in molecular medicine·2011
Same author

Expression of BRI2 mRNA and protein in normal human brain and familial British dementia: its relevance to the pathogenesis of disease.

Neuropathology and applied neurobiology·2008
Same author

Molecular chaperons, amyloid and preamyloid lesions in the BRI2 gene-related dementias: a morphological study.

Neuropathology and applied neurobiology·2006
Same author

Genetic alterations of the BRI2 gene: familial British and Danish dementias.

Brain pathology (Zurich, Switzerland)·2006
Same author

Chromosome 13 dementias.

Cellular and molecular life sciences : CMLS·2005
Same author

Platelet microparticles as carriers of soluble Alzheimer's amyloid beta (sAbeta).

Annals of the New York Academy of Sciences·2002
Same journal

Non-Alzheimer Aβ deposits in the human CNS: Implications with hypoxia and related conditions.

Brain pathology (Zurich, Switzerland)·2026
Same journal

Distinctly altered TRPC3 and TRPC6 expression patterns in human Alzheimer's disease cortex and hippocampus.

Brain pathology (Zurich, Switzerland)·2026
Same journal

Lewy bodies are surrounded by granulovacuolar degeneration bodies in dementia with Lewy bodies.

Brain pathology (Zurich, Switzerland)·2026
Same journal

A 3-year-old girl with a left optic nerve tumor.

Brain pathology (Zurich, Switzerland)·2026
Same journal

Chromosomal and immune dysregulation underlying granular mitosis in glioblastoma.

Brain pathology (Zurich, Switzerland)·2026
Same journal

Nearest-neighbors assisted unsupervised analysis for methylation array profiling for central nervous system tumors.

Brain pathology (Zurich, Switzerland)·2026
See all related articles

Prion protein (PrP) misfolding causes fatal neurodegenerative diseases. Specific PRNP gene mutations lead to Gerstmann-Sträussler-Scheinker disease (GSS) and prion protein cerebral amyloid angiopathy (PrP-CAA), characterized by amyloid formation.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Prion diseases are fatal neurodegenerative disorders affecting the central nervous system.
  • Cellular prion protein (PrP) is encoded by a conserved gene (PRNP) and is central to disease pathogenesis.
  • PrP misfolding, involving alpha-helix to beta-sheet conversion, drives amyloidogenesis.

Purpose of the Study:

  • To investigate the role of PrP conformational changes in prion disease.
  • To understand the molecular basis of amyloid formation in Gerstmann-Sträussler-Scheinker disease (GSS) and prion protein cerebral amyloid angiopathy (PrP-CAA).

Main Methods:

  • Analysis of PRNP gene mutations.
  • Characterization of amyloid fibril composition.

Related Experiment Videos

Main Results:

  • GSS and PrP-CAA are linked to specific PRNP point mutations.
  • Amyloid formation is prominent in GSS and PrP-CAA, less so in other prion diseases.
  • A 7 kDa peptide (PrP residues 81-150) is a major component of amyloid fibrils in GSS and PrP-CAA.

Conclusions:

  • PRNP mutations and subsequent PrP conformational changes are key in GSS and PrP-CAA pathogenesis.
  • Amyloid deposition, particularly involving PrP residues 81-150, is a hallmark of these specific prion diseases.
  • Understanding these mechanisms is crucial for studying neurodegenerative diseases.